Northeast Biodefense Center

东北生物防御中心（NBC）是一个由28个学术和研究机构（其中许多机构在纽约市大都会区彼此靠近）和13个美国政府和国际组织组成的bb350名研究人员组成的联盟。在过去的5年里，NBC的研究人员已经证明了他们致力于跨学科和机构边界的研究和培训项目，重点是生物防御和新发传染病以及应急准备。生产力的证据包括160篇出版物，15项发明披露，13项专利申请和5项产品开发许可。此次更新将包括42名研究人员和32个研究项目，分为6个科学主题领域：被动免疫治疗（主席：Arturo Casadevall， Einstein）；疫苗（主席：耶鲁大学约翰·罗斯）；诊断和病原体发现（主席：伊恩·利普金，哥伦比亚）；治疗学（主席：查尔斯·赖斯，洛克菲勒和霍华德·舒曼，哥伦比亚）；先天免疫（主席：David Levy，纽约大学和Adolfo Garcia-Sastre，西奈大学）和微生物发病机制（主席：Jorge E. Galan，耶鲁大学和Jorge Benach， Stony Book）。生物技术和制药合作伙伴在诊断和病原体发现（Agilent, Akonni, Cepheid, Xynostics, 454 Life Sciences），治疗学（Prosetta, Snowdon）和被动免疫治疗学（Regeneron）主题中有代表。这些工业联系不仅提供了智力资本和资源，而且为将NBC实验室的发现转移到更大的领域提供了途径，在那里它们可以为人类的健康和福利做出贡献。与国家和国际公共卫生机构的关系带来了额外的优势，这些机构提供了获得见解和临床材料（如诊断样本和PBMC）的独特途径，从而能够开展否则无法开展的工作。核心设施包括蛋白质表达、动物模型和蛋白质组学。我们还将投资于发展项目（创新试点项目）以及职业发展和培训项目，其中包括个人和团体职业发展奖励。作为公共卫生学院和国家卫生部的一个中心，全国应急中心对应急准备有着坚定的承诺和实际的理解。

The Northeast Biodefense Center (NBC) is a consortium of >350 investigators in 28 academic and research institutions (many of them in close proximity to one another in the greater NYC metro area), and 13 US based governmental and international organizations. Over the past 5 years, NBC investigators have demonstrated their commitment to working together across disciplines and institutional boundaries in research and training programs focused on biodefense and emerging infectious diseases as well as emergency preparedness. Evidence of productivity includes >160 publications, 15 invention disclosures, 13 patent applications and 5 licenses for product development. This renewal will comprise 42 investigators and 32 research projects organized into 6 scientific theme areas: Passive Immunotherapeutics (chair: Arturo Casadevall, Einstein); Vaccines (chair: John Rose, Yale); Diagnostics and Pathogen Discovery (chair: Ian Lipkin, Columbia); Therapeutics (chairs: Charles Rice, Rockefeller and Howard Shuman, Columbia,); Innate Immunity (chairs: David Levy, NYU, and Adolfo Garcia-Sastre, Sinai), and Microbial Pathogenesis (chairs: Jorge E. Galan, Yale, and Jorge Benach, Stony Book). Biotechnology and pharmaceutical collaborators are represented in the Diagnostics and Pathogen Discovery (Agilent, Akonni, Cepheid, Xynostics, 454 Life Sciences), Therapeutics (Prosetta, Snowdon), and Passive Immunotherapeutics (Regeneron) themes. These industrial links provide not only intellectual capital and resources but also a path for moving discoveries from NBC laboratories to a larger arena where they can contribute to human health and welfare. Additional strength derives from relationships with national and international public health agencies that provide unique access to insights and clinical materials (such as diagnostic samples and PBMC) that enable work that could not otherwise be pursuec. Core facilities will include Protein Expression, Animal Models, and Proteomics. We will also invest in Developmental Projects (innovative pilot projects) and in Career Development and Training Programs that include individual and group career development awards. As a Center based in a School of Public Health and a State Department of Health, the NBC has a firm commitment to and practical understanding of Emergency Preparedness.